Search results
11 sty 2024 · Arginine vasopressin disorder, formerly known as diabetes insipidus (DI), is a disease process that results in either decreased release of antidiuretic hormone (ADH, also known as vasopressin or AVP) or reduced response to ADH, causing electrolyte imbalances.
28 lis 2022 · Diabetes insipidus (DI) is a disorder characterized by excretion of large volumes of hypotonic urine. The underlying cause is either a deficiency of the hormone arginine vasopressin (AVP) in the pituitary gland/hypothalamus (central DI), or resistance to the actions of AVP in the kidneys (nephrogenic DI).
Diabetes insipidus is treated with demopressin/DDAVP in the following doses: oral or sublingual - 100-200µg (0.1-0.2mg) intranasal spray - 10=20µg. IM or IV injection - 1-2µg.
26 mar 2021 · The two main classifications of DI are central diabetes insipidus (CDI), characterized by a deficiency of the posterior pituitary gland to release ADH, and nephrogenic diabetes insipidus (NDI), characterized by the terminal distal convoluted tubule and collecting duct resistance to ADH.
Treatment of diabetes insipidus or primary polydipsia depends on the underlying aetiology and differs in central diabetes insipidus, nephrogenic diabetes insipidus and primary polydipsia. This review will discuss issues and newest developments in diagnosis, differential diagnosis and treatment, with a focus on central diabetes insipidus.
Objective: Titration of desmopressin can be challeng-ing during complex, lengthy surgical procedures in patients with chronic central diabetes insipidus (DI). Arginine vaso-pressin (AVP) may be the preferred treatment modality in these settings. No data currently exist on the use of AVP during lengthy operations.
Key points. Children with suspected or known diabetes insipidus (DI) must always have free access to water. Never restrict fluid intake. Urine output may not reflect hydration status. Close monitoring of electrolytes and fluid balance is required for inpatients with DI.
